"Visit the UCLA Health website for coronavirus updates."

During the past decade, UCLA Hematology Oncology conducted 43 clinical trials. In the 10-year time frame, 43 clinical trials started and 28 clinical trials were completed, i.e. on average, 65.1% percent of trials that started reached the finish line to date. In the past 5 years, 17 clinical trials started and 20 clinical trials were completed. i.e. 117.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "UCLA Hematology Oncology" #1 sponsor was "Pfizer" with 28 trials, followed by "Bristol-Myers Squibb" with 6 trials sponsored, "MacroGenics" with 4 trials sponsored, "Gilead Sciences" with 3 trials sponsored and "Genentech, Inc." with 3 trials sponsored. Other sponsors include 16 different institutions and companies that sponsored additional 24 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "UCLA Hematology Oncology" #1 collaborator was "Medivation, Inc." with 4 trials as a collaborator, "AstraZeneca" with 3 trials as a collaborator, "Bristol-Myers Squibb" with 2 trials as a collaborator, "Hoffmann-La Roche" with 2 trials as a collaborator and "Merck Sharp & Dohme LLC" with 2 trials as a collaborator. Other collaborators include 9 different institutions and companies that were collaborators in the rest 19 trials.

According to Clinical.Site data, the most researched conditions in "UCLA Hematology Oncology" are "Melanoma" (11 trials), "Renal Cell Carcinoma" (6 trials), "Advanced Solid Tumors" (5 trials), "Breast Cancer" (5 trials) and "Ovarian Cancer" (4 trials). Many other conditions were trialed in "UCLA Hematology Oncology" in a lesser frequency.

Most popular intervention types in "UCLA Hematology Oncology" are "Drug" (49 trials), "Biological" (15 trials), "Procedure" (2 trials), "Combination Product" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Docetaxel" (6 trials), "Nivolumab" (6 trials), "Placebo" (6 trials), "Pembrolizumab" (5 trials) and "Talazoparib" (5 trials). Other intervention names were less common.

The vast majority of trials in "UCLA Hematology Oncology" are 60 trials for "All" genders and 4 trials for "Female" genders.

Currently, there are NaN active trials in "UCLA Hematology Oncology". undefined are not yet recruiting, 9 are recruiting, 14 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 34 completed trials in UCLA Hematology Oncology, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in UCLA Hematology Oncology, 30 "Phase 1" clinical trials were conducted, 22 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".